An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors.

Trial Profile

An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2015

At a glance

  • Drugs Dactolisib (Primary) ; Everolimus (Primary)
  • Indications Advanced breast cancer; Male breast cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 01 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Nov 2014 Planned End Date changed from 1 Aug 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.
    • 18 Nov 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top